A61K 31/545
Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring
Official title: Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: [IMAGE cpc-sch-A61K-0953.gif] , e.g. cephalosporins, {cefaclor, or cephalexine}
A61K31/545 (Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring) appears on 872 US grants and 1,188 published applications in this corpus.
Search patents in A61K- Granted patents
- 872
- Published applications
- 1,188
- Assignees
- 583
- Inventors
- 2,358
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 22 | 0 |
| 1977 | 16 | 0 |
| 1978 | 16 | 0 |
| 1979 | 15 | 0 |
| 1980 | 8 | 0 |
| 1981 | 18 | 0 |
| 1982 | 4 | 0 |
| 1983 | 10 | 0 |
| 1984 | 12 | 0 |
| 1985 | 9 | 0 |
| 1986 | 6 | 0 |
| 1987 | 10 | 0 |
| 1988 | 5 | 0 |
| 1989 | 8 | 0 |
| 1990 | 9 | 0 |
| 1991 | 1 | 0 |
| 1992 | 7 | 0 |
| 1993 | 4 | 0 |
| 1994 | 3 | 0 |
| 1995 | 6 | 0 |
| 1996 | 4 | 0 |
| 1997 | 12 | 0 |
| 1998 | 12 | 0 |
| 1999 | 12 | 0 |
| 2000 | 9 | 0 |
| 2001 | 4 | 1 |
| 2002 | 17 | 20 |
| 2003 | 10 | 29 |
| 2004 | 5 | 38 |
| 2005 | 6 | 24 |
| 2006 | 5 | 28 |
| 2007 | 6 | 40 |
| 2008 | 6 | 38 |
| 2009 | 11 | 24 |
| 2010 | 20 | 30 |
| 2011 | 8 | 24 |
| 2012 | 18 | 28 |
| 2013 | 17 | 49 |
| 2014 | 30 | 80 |
| 2015 | 48 | 81 |
| 2016 | 51 | 83 |
| 2017 | 60 | 80 |
| 2018 | 44 | 81 |
| 2019 | 51 | 55 |
| 2020 | 50 | 69 |
| 2021 | 29 | 62 |
| 2022 | 32 | 67 |
| 2023 | 30 | 51 |
| 2024 | 28 | 50 |
| 2025 | 32 | 30 |
| 2026 | 16 | 26 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Ionic liquids for transdermal drug delivery6 Oct 2026US 12,752,009 B2Arizona Board of Regents
- Combinatory treatment29 Sep 2026US 12,746,216 B2Arivin Therapeutics Oy
- Use of membrane inhibitors to enhance vaccine development against enveloped viruses8 Sep 2026US 12,728,161 B2Cornell University
- CXCL8 inhibitors for use in the treatment of COVID-1926 May 2026US 12,636,268 B2Dompé Farmaceutici S.P.A.
- Boronic acid derivatives and therapeutic uses thereof26 May 2026US 12,636,297 B2Qpex Biopharma, Inc.
- Guanidinylated Amphiphilic Tobramycin Derivates and B-Lactam/B-Lactamase Inhibitor Combinations for Treatment of Pseudomonas Aeruginosa Infections8 Oct 2026US 2026/0306524 A1
- Tp0751 chimera-containing vaccine1 Oct 2026US 2026/0297141 A1University of Washington
- Boronic acid derivatives and therapeutic uses thereof17 Sep 2026US 2026/0272962 A1Qpex Biopharma, Inc.
- Method of Treating Cancer10 Sep 2026US 2026/0263405 A1University of Tennessee Research Foundation
- Multi-component pharmaceutical compositions and kits containing nitric oxide releasing compounds and methods of using same27 Aug 2026US 2026/0248819 A1KNOW Bio, LLC
Most cited
By later US patents
- Method for manufacturing a porous ceramic scaffold having an organic/inorganic hybrid coating layer containing a bioactive factor777US 8,734,831 B2Snu R&Db Foundation · 2014
- Pharmaceutical and cosmetic carrier or composition for topical application284US 6,911,211 B2Foamix Ltd. · 2005
- Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth243US 6,861,053 B1Cedars-Sinai Medical Center · 2005
- Probiotic recolonisation therapy240US 8,460,648 B22013
- Method for treatment of idiopathic inflammatory bowel disease (IIBD)229US 5,599,795 A1997